In the first article of this series we explored how collapsing trust in traditional evidence-based systems is fueling the recent boom in the unregulated peptide market. But this gray‑market peptide trend reveals more than a pushback against entrenched regulatory mechanisms. It exposes a deeper ethical divide in modern medicine: a clash between medical paternalism, where doctors …
